Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Quinvaxem in Healthy Vietnamese Children
NCT01362517Phase 3Completed
- Sponsor
- Crucell
- Start
- Apr 2010
- Primary completion
- Jul 2010
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of Quinvaxem in diphtheria, pertussis, Tetanus and 2 more, sponsored by Crucell. Primary endpoint: Immunogenicity - Seroprotection (Seroconversion for Pertussis) to Each Vaccine Component at 14 months. Started Apr 2010; status: completed.
02
Drugs
Quinvaxem
03
Conditions
diphtheriapertussisTetanushepatitis B (HBV)Haemophilus influenzae type b infection (Hib)
Beyond the preview
Go deeper on NCT01362517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01362517.